Abstract LB063: An integrated transomics approach reveals significant differences between EGFR inhibitors with the potential to identify novel targets to overcome EGFR resistance

MLA

Christopher J. Nicholson, et al. “Abstract LB063: An Integrated Transomics Approach Reveals Significant Differences between EGFR Inhibitors with the Potential to Identify Novel Targets to Overcome EGFR Resistance.” Cancer Research, vol. 83, Apr. 2023, p. LB063. EBSCOhost, https://doi.org/10.1158/1538-7445.am2023-lb063.

APA

Christopher J. Nicholson, Arudhir Singh, Caitlin Westberg Brown, Simon P. Fricker, Jon Hu, & Samantha Dale Strasser. (2023). Abstract LB063: An integrated transomics approach reveals significant differences between EGFR inhibitors with the potential to identify novel targets to overcome EGFR resistance. Cancer Research, 83, LB063. https://doi.org/10.1158/1538-7445.am2023-lb063

Chicago

Christopher J. Nicholson, Arudhir Singh, Caitlin Westberg Brown, Simon P. Fricker, Jon Hu, and Samantha Dale Strasser. 2023. “Abstract LB063: An Integrated Transomics Approach Reveals Significant Differences between EGFR Inhibitors with the Potential to Identify Novel Targets to Overcome EGFR Resistance.” Cancer Research 83 (April): LB063. doi:10.1158/1538-7445.am2023-lb063.